Surgery combined with radiotherapy for the treatment of solitary plasmacytoma of the rib: a case report and review of the literature

Rui Jia†, Lei Xue†, Huagang Liang, Kun Gao, Jian Li and Zhefeng Zhang*

Abstract

Solitary plasmacytoma of the bone, especially of a single rib, is a rare disease. We present the case of a 44-year-old Han Chinese man who was diagnosed with a solitary plasmacytoma of the bone located in the right sixth rib. The patient presented with a 4-year history of continuous pain in the right chest area and moderate fever lasting 7 days. A chest roentgenogram showed a solitary expanding lesion in the right thorax, and chest computed tomography revealed an osteolytic tumor in the chest wall. The patient underwent complete en-bloc resection of the chest wall, including the ribs, muscle, and parietal pleura. Histologically, the resected mass was composed of abundant neoplastic plasma cells, and the diagnosis was confirmed to be a plasmacytoma of rib. The examination of marrow cells showed 9% normal plasma cells among karyocytes without clonal disease. On postoperative day 14, the patient underwent thoracic radiotherapy with a total dose of 50 Gy. The patient remained asymptomatic during the 6-month follow-up period. Herein, we also review previous reports on solitary plasmacytomas of the rib. In summary, this report provides further insights for the diagnosis and effective treatment of this rare disease.

Keywords: Plasmacytoma, Rib, Surgery, Radiotherapy

Background

Solitary plasmacytoma of bone (SPB) is a rare localized neoplasm that accounts for only 5% of malignant plasma cell tumors [1]. SPBs typically occur in the vertebrae or pelvic bones, with presentation in the rib being less common [2, 3]. SPBs are characterized by the presence of only one or two isolated bone lesions with no evidence of disease dissemination and are generally considered to be curable with surgical resection and radiotherapy [4]. In most cases, SPBs present as osteolytic lesions of the bone on chest X-ray [5]. Herein, we report a case of solitary plasmacytoma of the rib (SPR) with unique clinical features.

Case report

A 44-year-old man visited our clinic complaining of continuous pain in the right chest area for 4 years and moderate fever for 7 days. He had no history of trauma or tuberculosis. A chest roentgenogram (Fig. 1a) and chest computed tomography (CT) (Fig. 2a and b) revealed a 6.11 cm x 9.33 cm, oval opacity in the right side of the chest, which was highly suspected to be an intra-thoracic tumor originating from the pleura or rib. Spiral CT three-dimensional reconstruction showed an osteolytic lesion in the right sixth rib (Fig. 2c and d), and abnormally increased uptake of radioisotope around the right sixth rib was observed in a bone scan (Fig. 1b). The radiologic features suggested a focal lytic lesion in the right sixth rib and limited pleura thickening (Fig. 2a and b). Peripheral blood examination showed no abnormalities (Table 1). Therefore, we decided to remove the lesion via a surgical approach for the treatment and diagnosis of the tumor. A standard posterolateral thoracotomy was performed along the fifth intercostal space. We completely resected the tumor and the surrounding fifth and seventh ribs with a safety margin of at least 3 cm. Adherent parietal pleura at the tumor site was also resected. During the operation, no pleural dissemination was found. Reconstruction of the chest wall defect was accomplished using a tension-free dacron patch (Johnson & Johnson, New Brunswick, NJ, USA). The gross
Fig. 1 Preoperative chest roentgenogram and bone scanning examinations. Chest roentgenogram showing a solitary expanding lesion in the right sixth rib (arrow, a). Abnormally increased uptake of radioisotope in the right sixth rib on a bone scan (b).

Fig. 2 Spiral computed tomography showing more detailed imagery and data. Three-dimensional computed tomographic image of the chest showing an irregular mass projecting into the thorax (arrow, a, b and c) and a focal lytic lesion in the sixth rib (black arrow, b). Spiral CT 3D reconstruction showing the absence of the right sixth rib (arrow, d).
Table 1 Summary of laboratory test results

| Investigation                        | Levels (normal range) |
|--------------------------------------|-----------------------|
| **Blood routine test**               |                       |
| White blood cell count               | 6.21 (3.5–9.5 × 10^9) |
| Red blood cell count                 | 4.35 (4.3–5.8 × 10^12) |
| Hemoglobin                           | 130 (130–175 g/l)     |
| Platelet count                       | 427 (125–350 × 10^3)  |
| Erythrocyte sedimentation rate       | 6 mm/1st hour          |
| **Blood biochemical examination**    |                       |
| Urea                                 | 5.49 mmol/L (3.2–7.0) |
| Creatinine                           | 74.1 μmol/L (44–115)  |
| Uric Acid                            | 224 μmol/L (210–430)  |
| Sodium                               | 139 mmol/L (137–147)  |
| Calcium                              | 2.33 mmol/L (2.10–2.60) |
| Magnesium                            | 0.82 mmol/L (0.8–1.0) |

| Electrophoresis of proteins and immunoglobulins | |
|--------------------------------------------------|
| Total protein                                    | 77.98 g/l (60–80) |
| Albumin                                          | 44.2 g/l (33–55)  |
| Globin                                           | 33.78 g/l (15–35) |
| M-protein (–)                                    |                      |
| Alfa1-globulin                                   | 4.1 % (1.4–2.9)     |
| Alfa2-globulin                                   | 12.5 % (7–11)       |
| Beta-globulin                                    | 11.3 % (8–13)       |
| Gammanab-protein                                 | 25 % (9–16)         |
| IgG                                              | 1310 mg/dl (751–1560) |
| IgA                                              | 212 mg/dl (82–453)  |
| IgM                                              | 164 mg/dl (46–304)  |
| Kappa light chain                                | 1050 mg/dl (629–1350) |
| Lambda light chain                               | 649 mg/dl (313–723) |
| K/L                                              | 1.62                 |
| Kappa light chain (urine)                        | 1.92 mg/dl (0–1.85) |
| Lambda light chain (urine)                       | <5.0 mg/dl (0–5)     |
| **Examination of marrow cell**                   |                       |
| Pathology: granulocytes, erythrocytes and giant cells are proliferous and active. Normal plasma cells are 9 % karyocytes. CD38, CD138, CD19 and CD45 (+), CD13, CD20, CD117, CD28 and CD56 (-). | |
| Chromosome examinations:46,XY (20), no clonal disorder | |
| RB-1 gene : no abnormalities                      |                       |
| IgH gene: no abnormalities                       |                       |
| TP53 gene: no abnormalities                      |                       |

pathology of the resected specimen showed an irregular, pale, soft, and friable tumor (Fig. 3a). Histological analysis of the resected tumor revealed abundant neoplastic plasma cells in the lesion (Fig. 3b). Immunohistochemical staining of the specimen showed positive staining for CD38 and CD138 (Fig. 3c and d). No M-protein in the serum or urine was found by immunoelectrophoresis. A biopsy of the bone marrow along with aspiration revealed that normal plasma cells accounted for 9 % of karyocytes, and these cells expressed CD38, CD138, CD19, and CD45 (Table 1). These characteristics were consistent with a diagnosis of plasmacytoma, excluding the possibility of multiple myeloma (MM).

Starting in postoperative day 15, radiation therapy with a total target dose of 50 Gy (2 Gy/d, 25 days) was administered to tissue surrounding the area of the resected tumor. The patient was followed up at 6 months after surgery and was relapse-free with no recurrence according to a chest CT scan (Fig. 4).

**Discussion**

SPB accounts for about 5 % of plasmacytomas [1, 6]. SPBs occur more commonly in males than in females, at an estimated ratio of 2:1 [7], and the median age of patients is approximately 55 years, which is about 10 years younger than patients with MM [5]. Thus far, few studies have compared SPRs with SPBs in other bones. We conducted an English literature search using the search terms “solitary plasmacytoma” and “rib” on Pubmed and found 18 case reports published between 1992 and 2014 [8–25] (Table 2). Among these SPR patients, 14 were male and four were female (male to female ratio, 3.5:1), and their ages ranged from 26–75 years (median, 52 years). The ratio of tumor occurrence in right ribs to left ones was 1.6:1, and the majority of tumors occurred on the fourth and fifth ribs (56 %).

The clinical presentation of SPR varies significantly. The most common symptom is pain due to progression of osteoclasia or oncothlipsis [8, 9, 11, 12, 14, 15, 21, 23, 25], but some cases are asymptomatic and found based on a chest mass during physical examinations [13, 14, 17, 19, 20]. Other chief complaints include limb weakness [16, 22], Horner’s syndrome [24], and axillary lymphadenectasis [18]. All the reported cases showed osteolytic ribs on radiologic examination, including 12 cases with a chest mass [9–14, 17, 19–21, 24, 25] and two with pleural effusion [8, 12]. In our case, CT showed an irregular intrathoracic mass with heterogeneous density in the right sixth osteolytic rib with adjacent pleural thickening.

The currently recommended diagnostic criteria [5] for SPB include the following: (i) clinical and radiological evidence of a single area of bone destruction on skeletal survey; (ii) histological confirmation of plasma cell histology; (iii) normal marrow without clonal disease; (iv) absence of anemia, hypercalcemia, or renal impairment attributable to myeloma; and (v) absent or low serum or urinary level of monoclonal protein (called Bence-Jones protein) and preserved levels of uninvolved immunoglobulins. Therefore, the diagnosis of our case was based on the following findings: osteolytic rib observed by imaging, histopathological
evidence of plasmacytoma, and absence of MM features on bone marrow examination.

Surgical intervention is the first choice of treatment for SPB, and a complete resection is expected to be curative. Bataille et al. [1] reported 114 cases of solitary myeloma and showed that the lowest incidence of progressive disease was observed in patients with peripheral solitary plasmacytoma treated with surgery plus an adequate dose of radiation therapy. Aviles et al. [26] demonstrated that most patients treated with adequate radiation therapy alone will develop MM within 3 years. With respect to the radiation dose, Mendenhall et al. [27] reported that the local failure rates were 6 and 31% in patients with a solitary plasmacytoma treated with doses of 40 Gy or greater and doses below 40 Gy, respectively. It is recommended that SPB be treated with radical radiotherapy, encompassing the tumor volume shown on magnetic resonance imaging with a margin of at least 2 cm and treated to a dose of 40 Gy in 20 fractions. For a SPB with a tumor size of >5 cm, a higher dose of up to 50 Gy in 25 fractions should be considered [7].

The role of adjuvant chemotherapy in preventing progression to MM remains unclear. Some reports suggest that adjuvant chemotherapy does not affect the incidence of conversion from SPB into MM but could delay its progression to MM [4]. Patients not responsive to radiotherapy could be treated with chemotherapy, with a similar approach to that used in the treatment of MM [7], but the effectiveness of chemotherapy for SPR remains to be determined. Our patient received a complete en-bloc resection and postoperative 50 Gy of radiotherapy, with no relapse at 6 months after surgery,

![Gross specimen and pathological findings. The tumor (arrow) was resected with the surrounding fifth to seventh ribs, with a safety margin of at least 3 cm (a). Microscopic view shows abundant neoplastic plasma cells (H&E, ×400) (b). Immunohistochemical staining showed that the specimen is positive for CD38 (c) and CD138 (d).](image)

![Follow-up chest computed tomography scan. No residual tumor or recurrence was found in the lungs (a) or chest wall (b).](image)
| Reference     | Sex | Age | Symptom                                         | Location | Radiologic findings | Treatment | Prognosis                           |
|---------------|-----|-----|-------------------------------------------------|----------|--------------------|-----------|-------------------------------------|
| Caffery T,2014 [8] | M   | 33  | Chest pain                                      | R-5th rib | OR and pleural effusion | R         | Relapse-free at 2-year follow-up   |
| Tajima K,2014 [9] | M   | 71  | Chest pain, mild dyspnea                        | R-3th rib | OR and CWT          | S         | Relapse-free for 1.5 years follow-up |
| Santos VM,2012 [10] | F    | 65  | Breathlessness, discrete expectoration          | R-4th rib | OR and CWT          | Plasmapheresis | Pulmonary acute edema for progressive disease into MM |
| Lee HY,2012 [11] | M   | 73  | Chest pain                                      | R-5th rib | OR and CWT          | S + R     | No mention                          |
| Singal R,2011 [12] | F    | 43  | Chest pain, coughing                           | R-5th rib | OR, CWT and pleural effusion | S         | Relapse-free for 2.5 years follow-up |
| Kodate M,2010 [13] | M   | 70  | Chest mass                                      | R-4th rib | OR and CWT          | S + R + C  | Relapse-free for 2 years and 9 months follow-up |
| Pattanayak L,2010 [14] | M    | 60  | Chest pain                                      | R-4th rib | OR and CWT          | R         | Remission after 8 months           |
| Ketata W,2009 [15] | M    | 60  | Dyspnea, dry cough, chest pain                  | L-first rib | OR                       | S + R     | Remission after 8 months           |
| Palao S,2006 [16] | M    | 32  | Progressive symmetrical paraparesis and paresthesia in feet (demyelinating- polyradiculoneuropathy) | L-3th rib | OR                       | S + R     | Asymptomatic after surgery         |
| Bousnina S,2006 [17] | M    | 52  | Chest mass                                      | L-6th rib | OR and CWT          | R         | Remission at 1 year                |
| Wilkinson S,2003 [18] | M    | 35  | Axillary-lymphadenopathy (Castleman's disease)  | R-10th rib | OR                       | S + R     | Relapse-free at 2-year follow-up   |
| George SM,2002 [19] | M    | 29  | Chest mass                                      | R-11th rib | OR and CWT         | S         | No mention                          |
| Sato Y,2001 [20] | M    | 46  | Chest mass                                      | R-5th rib | OR and CWT          | S         | No mention                          |
| Kadokura M,2000 [21] | M    | 44  | Left back pain                                  | L-7th rib | OR and CWT          | S + C     | Relapse-free at 2-year follow-up   |
| Mankodi AK,1999 [22] | F    | 26  | Distal limb weakness                            | L-6th rib | OR                       | S         | Improvement in symptoms at 6 months of follow-up |
| Hirai T,1995 [23] | F    | 72  | Chest pain                                      | R-5th rib | OR                       | S         | Relapse-free for 1.7 years of follow-up |
| Carvajal,1994 [24] | M    | 45  | Horner's syndrome                               | L-first rib | OR and CWT         | S + R     | Relapse-free for 2 years of follow-up |
| Ikeda T,1992 [25] | M    | 75  | Chest pain                                      | L-4th rib | OR and CWT          | R         | Develop into MM                    |

S surgery, R radiotherapy, C chemotherapy, OR Osteolytic rib, CWT Chest-wall tumor
indicating that our surgery plus radiation therapy was efficacious.

It is generally accepted that patients with SPB have an indolent course of disease, with a median survival time of 10.7 years and 5-, 10-, and 20-year survival rates of 75, 52, and 37 %, respectively [5]. However, Warnas et al. [28] reported that in a study of 127 SPB patients followed up for 7–28 months (median, 56 months), 85 patients (67 %) progressed to MM and 27 patients (21 %) died of progression.

Conclusion

In conclusion, SPRs show an earlier average age of onset and higher male to female incidence ratio than SPBs located in other bones, according to the literature review. SPRs should be considered when confronted with a lytic tumor of the rib. The treatment is based on surgery and radiotherapy. SPRs are often resectable, and the prognosis is generally good and dominated by the risk of progression to MM.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

SPB: Solitary plasmacytoma of bone; CT: Computed tomography; SPR: Solitary plasmacytoma of the rib; MM: Multiple myeloma.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ZTF, study concept and design; RJ and LX, drafting and finalization of the manuscript, preparation of the figures, acquisition of data, and analysis and interpretation of data; KG, HCL, and JL, critical revision of the manuscript for important intellectual content and material support; and all authors read and approved the final manuscript.

Authors’ information

Rui Jia, Master’s degree, attending surgeon; Lei Xue, Associate Chief Physician; Huagang Liang, PhD, Superintendent of the Institution, chief surgeon; Kun Gao, Master’s degree, associate chief surgeon; Jun Li, Master’s degree, resident surgeon; Zhefeng Zhang, PhD, attending surgeon.

Acknowledgements

We thank our colleagues in the Departments of Thoracic Surgery and Pathology of our hospital for helpful discussions.

Received: 17 March 2015 Accepted: 5 October 2015

Published online: 13 October 2015

References

1. Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer. 1981;48:845–51.
2. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. In J Radiat Oncol Biol Phys. 1989;16:43–8.
3. Woodruff RK, Malpas JS, White FE. Solitary plasmacytoma II: Solitary plasmacytoma of bone. Cancer. 1979;43:2394–7.
4. Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer. 1990;26:363–71.
5. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexandrian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037–44.
6. Wilthous E. The natural history of extramedullary plasmacytoma and its relation to solitary plasmacytoma of bone and myelomatosis. Medicine (Baltimore). 1976;55:217–38.
7. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717–26.
8. Gaffney T, Foy M. Plasmacytoma presenting as missing rib on chest film: a case report and review of the literature. J La State Med Soc. 2014;166:63–6.
9. Tajima K, Uchida N, Azuma Y, Okada T, Sasamoto H, Yokoo K, et al. Surgical resection of a solitary plasmacytoma originating in a Rib. Ann Thorac Cardiovasc Surg. 2014;20:609–12.
10. Santos VM, Brito EF, Pas BC, Leal CT. Rib plasmacytoma and IgA multiple myeloma with hyperthyroidism syndrome. Arch Iran Med. 2012;15:517–9.
11. Lee HY, Kim JI, Kim KN. Solitary plasmacytoma of the rib. Korean J Thor Cardiovasc Surg. 2012;4:269–71.
12. Singal R, Dalal U, Dalal AK, Attri AK, Gupta S, Raina R. Solitary plasmacytoma of the rib: A rare case. Lung India. 2011;28:309–11.
13. Kodate M, Takagishi T, Osaki T. Plasmacytoma of chest wall. Kyobu Geka. 2010;63:879–82.
14. Pattanayak L, Samantaray S, Rout N. Solitary plasmacytoma of the rib: a rare cytological detection. Indian J Cancer. 2010;47:485–6.
15. Ketata W, Triki F, Msaid S, Ayadi L, Fassi O, Ayadi H, et al. A rare localization of solitary plasmacytoma. Rev Pneumol Clin. 2009;65:165–8.
16. Palao S, Marjuyan J, López J, Galeja P. Solitary costal plasmacytoma: a rare cause of subacutec demyelinating polyradiculoneuropathy. Neurologia. 2006;21:265–8.
17. Boussina S, Zendah I, Marniche K, Yalaoui S, El Mezni F, Megdiche ML, et al. Solitary plasmacytoma of the rib: A rare tumor not to miss. Rev Pneumol Clin. 2006;62:243–6.
18. Wilkinson S, Forrester-Wood CP. Surgical resection of a solitary plasmacytoma originating in a rib of a patient with Castleman’s disease. Ann Thorac Surg. 2003;75:1018–9.
19. George SM, Ratnakar KS, Shome DK, Nair R, Al Ajmi A. Plasmacytoma of the rib in young male. Asian Cardiovasc Thorac Ann. 2002;10:282–4.
20. Sato Y, Haru M, Ogino H, Kaj M, Yamakawa Y, Wakita A, et al. CT-pathologic correlation in a case of solitary plasmacytoma of the rib. Radiat Med. 2001;19:363–5.
21. Kadokura M, Tani N, Nonaka M, Yamamoto S, Katoaka D, Kushima M, et al. A surgical case of solitary plasmacytoma of rib origin with bicalonal gammopathy. Jpn J Clin Oncol. 2000;30:391–5.
22. Mankodi AK, Rao CV, Katrak SM. Solitary plasmacytoma presenting as peripheral neuropathy: a case report. Neurol India. 1999;47:234–7.
23. Hira T, Hamada Y, Kanou T, Kobayashi J, Endo K, Morishita Y. Solitary plasmacytoma of the rib-a case report and review of Japanese literatures. Nihon Kyobu Geka Gakkai Zasshi. 1995;43:205–9.
24. Carvajal Balaguera JJ, Mallagray Casas S, Dancausa Monge A, Canto Romero JJ. Horner’s syndrome associated with a solitary bone plasmacytoma of the first rib. Arch Bronconeumol. 1999;34:10–3.
25. Ikeda T, Minaoka Y, Inai H, Yokawa S, Nomoto H, Tsujimoto M. A case of plasmacytoma of the ribs with intrathoracic tumors. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:133–7.
26. Avilés A, Huerta-Guzmán J, Delgado S, Fernández A, Díaz-Maqueo JC. Improved outcome in solitary bone plasmacytoma with combined therapy. Hematol Oncol. 1996;14:111–2.
27. Mendenhall WM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys. 1980;6:497–501.
28. Warrens R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:647–51.